Cervical cancer is a disease affecting thousands of women in the UK with around 3,200 new cases diagnosed every year, can developments in cervical screening and digital cytology help?
Neil Macdonald, CEO at Thrive, explains how using the Impact Evaluation Standard to report on social value in government contracts can actually lead to far better outcomes for communities and for suppliers.
Dr Helen M Rowe at the Centre for Immunobiology at the Queen Mary University of London looks towards unlocking dark matter for the potential to boost immune responses in humans.
The Imaging and Radiation Oncology Core is part of the U.S. National Cancer Institute’s clinical trial program and provides quality assurance for trials with radiation oncology and/or imaging.
Dayna Arnold, Project Manager at Zest Consult, discusses the benefits of using a synthetic data approach to machine learning as an innovative solution for increasing the availability, accuracy & security of more cost effective data.
What’s the return on basic research spending? What can policymakers do to make basic research more valuable, beyond simply spending more taxpayer money? And what role will private innovation have?.
Peter Bretscher, from the University of Saskatchewan looks at whether mouse models of cutaneous leishmaniasis are pertinent for vaccination against and treatment of AIDS, infectious diseases, and cancer.
Emily Davenport and Arpita Bose discuss the case for freshwater wetlands as vital pieces of the solution for climate change and sustainable energy synthesis.
Sabine Mai and Aline Rangel-Pozzo, at the CancerCare Manitoba Research Institute and The University of Manitoba, Winnipeg, Canada, discuss genomic instability in relation to 3D spatial organization of telomeres.
